VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) today announced that its Chief Operating Officer, Michael R. Martin will present a corporate overview of the company at the 2016 Bloom Burton & Co. Healthcare Investor Conference, taking place May 2-3, 2016 in Toronto at the Sheraton Centre Toronto Hotel.
Aurinia Presentation Details
|Date:||Monday, May 2, 2016|
|Time:||11:00am. Eastern Daylight Time|
|Location:||Sheraton Hall B|
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently collecting data in its 265 patient Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Voclosporin is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,000 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.
Visit www.auriniapharma.com for more information.